Beranda › Kanker Ginjal (Karsinoma Sel Renal) › Idaho
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di Idaho
4 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi di Idaho.
Kota di Idaho
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- dan 9 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- dan 3 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Saint Alphonsus Cancer Care Center-Nampa, Nampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05327686Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Saint Luke's Cancer Institute - Boise, Boise
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- Saint Luke's Cancer Institute - Fruitland, Fruitland
- dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06661720Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.